BC Week In Review | Feb 21, 2011
Company News

sanofi-aventis sales and marketing update

sanofi-aventis said it withdrew Anzemet dolasetron from five countries. The serotonin (5-HT3) antagonist will still be marketed in eight countries, including the U.S., to prevent nausea and vomiting. Further terms were not disclosed. sanofi-aventis Group...
BC Week In Review | Jan 3, 2011
Clinical News

Anzemet dolasetron regulatory update

FDA issued a drug safety communication warning that sanofi's IV Anzemet dolasetron should not be used to prevent nausea and vomiting associated with cancer chemotherapy (CINV) after data demonstrated that the drug can increase the...
BC Week In Review | Sep 17, 2007
Company News

sanofi-aventis, U.S. Department of Justice gastrointestinal news

SAN agreed to pay $182.8 million plus interest to settle a suit alleging that the company inflated the average wholesale price (AWP) for antiemetic drug Anzemet dolasetron, which federal health care programs use to establish...
BC Week In Review | Dec 12, 2005
Company News

Akzo Nobel NV, sanofi-aventis sales and marketing update

AKZ's Organon USA Inc. unit (Roseland, N.J.) received rights to promote SAN's Anzemet dolasetron to anesthesiologists. The serotonin (5-HT3) antagonist is approved to treat and prevent post-operative nausea and vomiting (PONV). Akzo Nobel NV (Euronext:AKZ;...
BC Week In Review | Jan 5, 2004
Clinical News

Aloxi palonosetron: Phase III data; marketed

Subset analysis from 2 previously reported Phase III trials showed that in 695 patients with breast cancer, 50% of those treated with Aloxi had a complete response during the 0-120 hour period compared to 34%...
BC Week In Review | Jan 5, 2004
Clinical News

Aloxi palonosetron: Phase III data; marketed

Compiled safety data from a dose-ranging Phase II study and 3 Phase III trials showed that for the 633 patients receiving the approved 0.25 mg dose of Aloxi, the most frequently observed adverse reaction was...
BioCentury | Aug 25, 2003
Regulation

CMS shopping list

CMS shopping list Drug Company Rank 2002 CMS charges ($M) (A) 2002 U.S. sales ($M) 2001 avg AWP Spread (B) Epogen epoetin alfa (C) Amgen NA $1,400 $2,300 NA NA Procrit epoetin alfa Johnson &...
BioCentury | Jul 28, 2003
Product Development

MGI's plan to grab market

When MGI Pharma Inc. launches its Aloxi palonosetron in September, the compound will be the fourth serotonin (5-HT3) antagonist on the market to prevent chemotherapy-induced nausea and vomiting - an indication with only moderate expected growth....
BC Week In Review | Jun 9, 2003
Clinical News

Palonosetran: Phase III

MOGN and Helsinn presented data from study 99-03, an international Phase III double-blind trial in 563 patients receiving high or low-dose palonosetron 5-HT3 serotonin receptor antagonist or ondansetron , a marketed 5-HT3 antagonist to prevent CINV....
BioCentury | Jun 9, 2003
Product Development

Treating the treatments

Lessons from ASCO Treating the treatments While targeted therapies were hot topics at this year's American Society of Clinical Oncology meeting, systemic cancer therapies aren't going to be usurped from their entrenched positions in treatment...
Items per page:
1 - 10 of 11